Clinical and Economic Outcomes of Cannabis-Based Formulations (CBD and CBD/CBG) for Autism Spectrum Disorder (ASD): A HEOR Model Study Analysis
Author(s)
ELIO TANAKA, Sr., MD1, Romeu Kuabara, MD2, Luis Claudio Rodrigues Marrochi, MD3, ANTONIO CARDONE ROMARIZ, PhD3, Carlos Alexandre Richter, MD4, Reinaldo Flávio da Costa Ramalho, MD5.
1MEDICAL AUDIT, TNK MEDICAL AUDIT INSTITUTION, CURITIBA, Brazil, 2RESEARCH, TNK, GOIANIA, Brazil, 3RESEARCH, TNK MEDICAL AUDIT INSTITUTION, CURITIBA , PARANÁ, Brazil, 4HEOR STUDENT, TNK, FLORIANÓPOLIS, Brazil, 5HEOR STUDENT, TNK, BELO HORIZONTE, Brazil.
1MEDICAL AUDIT, TNK MEDICAL AUDIT INSTITUTION, CURITIBA, Brazil, 2RESEARCH, TNK, GOIANIA, Brazil, 3RESEARCH, TNK MEDICAL AUDIT INSTITUTION, CURITIBA , PARANÁ, Brazil, 4HEOR STUDENT, TNK, FLORIANÓPOLIS, Brazil, 5HEOR STUDENT, TNK, BELO HORIZONTE, Brazil.
OBJECTIVES: Our analysis showed promising potential for clinical and economic outcomes of CBD and CBD/CBG combinations . The widespread use of it and increasingly in other situations, such as ASD , leads us to analyze economic/financial outcomes in order to add better/clearer informations to decision-makers.
METHODS: We used data from the national literature regarding ASD and the costs with repercussions on the quality of life of this situation. Although data on clinical and economic outcomes are scarce, we reviewed what was possible to get an idea of the effective costs of using cannabidiol in ASD people.
RESULTS: While data on clinical and economic outcomes is still limited, some studies have started to explore this area . In Brazil, it's estimated that approximately 2 million people live with ASD . This estimate is based on data from the Centers for Disease Control and Prevention (CDC) in the United States, which suggests that 1% to 2% of the global population is affected by ASD . Economic impact data still limited, CBD treatment costs can vary widely pending on factors like the dosage, the form of CBD used (e.g., oil, capsules, etc.), and the duration of treatment. Additionally, the legal and regulatory landscape in Brazil can also impact the availability and pricing of CBD products. CBD oil prices range from USD 10 TO USD 60 ( RATE 1:5 ) per bottle, with higher concentrations typically costing more. The global Brazil's economic impact estimate 20.000 thousand to 120.000 thousand USD . Regarding Insurance Coverage , currently, CBD treatments are not typically covered by health insurance in Brazil, meaning the full cost would need to be out-of-pocket.
CONCLUSIONS: Studies highlight that CBD-rich cannabis extracts may be beneficial in ASD, but they are not without side effects. Additional analyses need to be done as a whole .
METHODS: We used data from the national literature regarding ASD and the costs with repercussions on the quality of life of this situation. Although data on clinical and economic outcomes are scarce, we reviewed what was possible to get an idea of the effective costs of using cannabidiol in ASD people.
RESULTS: While data on clinical and economic outcomes is still limited, some studies have started to explore this area . In Brazil, it's estimated that approximately 2 million people live with ASD . This estimate is based on data from the Centers for Disease Control and Prevention (CDC) in the United States, which suggests that 1% to 2% of the global population is affected by ASD . Economic impact data still limited, CBD treatment costs can vary widely pending on factors like the dosage, the form of CBD used (e.g., oil, capsules, etc.), and the duration of treatment. Additionally, the legal and regulatory landscape in Brazil can also impact the availability and pricing of CBD products. CBD oil prices range from USD 10 TO USD 60 ( RATE 1:5 ) per bottle, with higher concentrations typically costing more. The global Brazil's economic impact estimate 20.000 thousand to 120.000 thousand USD . Regarding Insurance Coverage , currently, CBD treatments are not typically covered by health insurance in Brazil, meaning the full cost would need to be out-of-pocket.
CONCLUSIONS: Studies highlight that CBD-rich cannabis extracts may be beneficial in ASD, but they are not without side effects. Additional analyses need to be done as a whole .
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO42
Topic
Clinical Outcomes, Economic Evaluation, Medical Technologies
Topic Subcategory
Clinician Reported Outcomes, Comparative Effectiveness or Efficacy, Performance-based Outcomes, Relating Intermediate to Long-term Outcomes
Disease
Alternative Medicine, Genetic, Regenerative & Curative Therapies, Mental Health (including addition), Neurological Disorders